Table 1 Baseline patient characteristics
patient age (years); median (range) | 71 (45-84) |
|---|---|
planning target volume (cm3); median (range) | 336 (169-631) |
PSA (ng/ml); median (range) ≤10 ng/ml; n (%) | 8 (1.2-150) 178 (62) |
biopsy Gleason score <7; n (%) | 185 (65) |
clinical T-stage ≤2a; n (%) | 237 (83) |
low risk (PSA≤10 ng/ml; Gleason score <7; clinical T-stage ≤2a); n (%) | 106 (37) |
intermediate risk (PSA 10-20 ng/ml or Gleason score = 7 or clinical T-stage 2b-c); n (%) | 101 (35) |
high risk (two risk factors or PSA>20 ng/ml or Gleason score >7 or clinical T-stage >2c); n (%) | 79 (28) |
neoadjuvant hormonal therapy; n (%) | 90 (32) |
any documented comorbidity;; n (%) | 179 (63) |
hypertension; n (%) | 74 (26) |
coronary heart disease; n (%) | 76 (27) |
diabetes; n (%) | 34 (12) |
chronic obstructive pulmonary disease; n (%) | 31 (11) |
haemorrhoids; n (%) | 17 (6) |
stroke in past history; n (%) | 12 (4) |
peripheral arterial disease; n (%) | 10 (4) |
chronic renal failure; n (%) | 8 (3) |